

---

# Index

## A

- Abnormal stratum corneum acidification, 72
- Acitretin, 67
- ACLF. *See* Adult Congregate Living Facility (ACLF)
- Actinic keratosis (AKs)
  - atypical epidermal keratinocytes, 89
  - dipyrimidine site, 90
  - epidemiology, 89–90
  - melanin, 90
  - prevention, 90
  - SCC, 89
  - treatment (*see* Treatment, AKs patients)
- Adalimumab, 67
- Adult Congregate Living Facility (ACLF), 81
- Adverse drug events (ADEs), 14–16
- Aging
  - cutaneous health, 71
  - epidermal barrier, 33
  - herpes zoster (shingles), 12
  - NF- $\kappa$ B, 60
  - pharmacodynamics
    - dermatologic medications, 7
    - geriatric syndromes, 7
    - systemic immunosuppressive agents, 7–11
  - pharmacokinetics
    - hepatic metabolism, 2–6
    - medication absorption, 1–2
    - renal clearance, 2, 7
    - volume of distribution, 2
  - physiological changes, 34
  - skin, 55–56 (*see also* Skin aging)
- AKs. *See* Actinic keratosis (AKs)
- American College of Rheumatology (ACR), 12, 13
- Andropause, 59
- Antihistamines, 36
- Anti-IL-31 receptor antibody, 37
- Anti-TNF agents, 13
- Aquaporin 3 (AQP3) expression, 72

## B

- Basal cell carcinoma (BCC)
  - in older adults
    - cryotherapy monotherapy, 99
    - electrodesiccation and curettage, 99

- electronic surface brachytherapy, 99
- 5-fluorouracil/imiquimod, 98
- Hedgehog signaling pathway, 99
- ingenol mebutate, 98
- keratinocytic cancers, 97
- MAL-PDT, 99
- non-advanced BCC treatments, 97, 98
- skin cancer, 97–98
  - stage I and II, 97
  - superficial and nodular BCC, 98
- 11- $\beta$ -hydroxysteroid dehydrogenase type 1 (11 $\beta$ -HSD1), 59
- Biologics medications, 67–68
- Blood urea nitrogen (BUN), 2
- Brittle nails disease
  - biotin supplementation, 44
  - cosmetic nail hardeners, 44
  - dermatologic/systemic disease, 43
  - elderly individuals, 43
  - environmental factors, 43
  - Equisetum avense*, 44
  - Genadur*®, 44
  - keratin, 43
  - Nu-Vail*®, 44
  - onychoschizia, 43
  - treatment, 44
  - urea and lactic acid, 44

## C

- CAM. *See* Complementary and alternative medicine (CAM)
- Cannabinoid receptor, 37
- Cholesterol, 74
- Chronic pruritus, 37
- Cockcroft-Gault equation, 2
- Common dermatologic medications, 3–6
- Complementary and alternative medicine (CAM), 25
  - biomedicalization, 18
  - corticosteroid-induced osteoporosis prophylaxis, 25
  - in dermatology, 18
  - geriatrics resources, 25–26
  - health-care approaches, 17
  - health-care providers, 18
  - natural products, 17, 18

- Complementary and alternative medicine  
(CAM) (*cont.*)  
 older patients, 18  
 prescribing/polypharmacy, 26  
 prescription assistance, 26  
 prescription medications, 18, 19  
 rosacea and psoriasis, 18  
 safety and efficacy, 17
- Connective tissue growth factor (CTGF), 57
- Cortisol, 58, 59
- CTGF. *See* Connective tissue growth factor (CTGF)
- Cutaneous  
 anti-inflammatory activities, 36  
 chemopreventive measures, 14  
 eruption, 46  
 inflammation, 33  
 myxoid cysts, 48
- Cutaneous squamous cell carcinoma (CSCC), 99–100
- Cyclosporine, 67
- Cytochrome P450 (CYP)  
 CYP3A4, 47  
 dermatologic medications, 3–6  
 in humans, 2
- D**
- Darier's disease, 43
- Deoxyuridine 5-monophosphate (DUMP), 91
- Dermatogeriatrics, 19, 83
- Dermatology  
 aging skin conditions, 73  
 AKs treatment, 93  
 supportive skin care, 71  
 urea, 75
- Dermato-pharmacology  
 aging (*see* Aging)  
 CAM (*see* Complementary and alternative medicine (CAM))  
 ethical considerations, older adults, 14–15  
 geriatric patients, 24  
 geropharmacology research, 24  
 infectious disease prophylaxis, 12–13  
 medication errors  
 geriatric population, 15  
 hospitalization, 15  
 inappropriation, 15–16  
 medication non-adherence, 17  
 overuse, 16  
 underprescription, 16–17  
 prescribing medications, 24  
 systemic corticosteroid side effects and prophylaxis,  
 10, 12  
 TNF antagonists, 13
- Dermatophytoma, 46
- Dermatophytosis (tinea), 16
- Dexpanthenol (vitamin B5), 74
- Diclofenac, 92–93
- Director of nursing (DON), 80
- Distal interphalangeal (DIP) joint, 48
- DUMP. *See* Deoxyuridine 5-monophosphate (DUMP)
- E**
- Efinaconazole, 45
- Elderly  
 adalimumab and etanercept, 67–68  
 cyclosporine, 67  
 methotrexate, 66–67  
 moisturizers, 73  
 nail-associated neoplasms  
 asymptomatic lesions, 48  
 clinicians, 50  
 DIP joint, 48  
 glomus tumors, 48  
 HPV infection, 49  
 Hutchinson's sign, 50  
 longitudinal melanonychia, 50  
 magnetic resonance imaging, 48  
 melanoma, 49  
 Mohs micrographic surgery, 49  
 squamous cell carcinoma, 49  
 subungual lesions, 49  
 tumors, 47–48  
 SCCIS, 100  
 xerosis and pruritus, 72
- Electrodesiccation, 99
- Epidermal barrier, 12, 33
- Epidermal growth factor (EGF), 57
- Eruption of senescence, 33–34
- Estimated GFR (eGFR), 2
- Estrogen depletion, 59
- European multicenter randomized controlled trial of  
 photodynamic therapy (MAL-PDT), 92, 99
- Extravascular space, 2
- Extrinsic factor, 71
- F**
- Fibroblast growth factor (FGF), 57, 58
- 5-Fluorouracil (5-FU), 91, 93, 98
- Food and Drug Administration (FDA), 2, 44, 46, 47
- G**
- Geriatric  
 cyclosporine, 67  
 long-term care, 81  
 phototherapy, 66  
 psoriasis, 65
- Geriatric dermatology prescription cycle  
 coordinate care, 23–24  
 dose adjustment and titration, 23  
 LOE IV, 20  
 medication interactions, 22  
 neomycin, 21  
 non-dermatology medications, 19  
 patient and caregiver, 22–23  
 patient's medications and health status, 20  
 physical ability, 22  
 risk vs. benefit, 21–22  
 and schedule strategic follow up, 23–24  
 transitions of care, 20
- Geriatric ethical dilemmas, 15

Geriatric syndromes, 7  
 Geropharmacology  
   ethical principles, 15  
   older adult patients, 24  
   physiologic principles, 1  
 Glomerular filtration rate (GFR), 2, 60  
 Glomus tumors, 48  
 Glucocorticoid signaling, 59  
 Glycerol, 74

## H

Hair follicle stem cells (HFSCs), 56, 57  
 Histamine H<sub>2</sub> receptor, 37  
 Hodgkin's lymphoma, 36  
 Hormone replacement, 58  
 Human immunodeficiency virus (HIV), 13  
 Hutchinson's sign, 50  
 Hypothyroidism, 55

## I

*IGFR1* genes, 60  
 IGF signaling, 60  
 Imiquimod, 91, 98  
 Immune system, 7  
 Infectious Disease Society of America (IDSA), 13  
 Ingenol mebutate, 91–92, 98  
 Intracellular matrix composition, 74  
 Intrinsic factor, 71  
 Ipilimumab, 101  
 Itraconazole, 46–47

## J

Jessner's solution, 93

## K

Kappa-opioid receptor, 37  
*klotho* mice, 56

## L

Lactic acid, 75  
 Lanolin, 75  
 Level of evidence (LOE), 8–10  
 Long-term care  
   in America, 77  
   dermatology, 82  
   DNR, 81  
   geriatric, 81  
   legal and financial burden, 77–78  
   medical decision-making, 81  
   neurodermatitis, 82  
   nursing homes (*see* Nursing homes)  
   pressure ulcers, 82  
   and risk assessment tools, 83  
   scabies and norwegian scabies, 82  
   treatment, 82–83  
 Lotrisone, 21

## M

Mature skin, 67  
 Melanoma  
   advanced BCC/BRAF inhibitors, 97  
   incidence rates, 98  
   non-melanoma skin cancer, 97  
   in older adults, 101  
 Methotrexate, 66–67  
 Modification of Diet in Renal Disease (MDRD) formula,  
   2, 7, 24  
 Moisturizers, 73–74  
 Muehrcke's lines, 41

## N

NAFLD. *See* Nonalcoholic fatty liver disease (NAFLD)  
 Nail changes, older adults, 41–42  
 Nail disorders, 41, 43  
 Nail melanoma, ABCDEFs of, 50  
 Neurodegenerative disorders, 33  
 Neurodermatitis, 82  
 NF- $\kappa$ B, 57–58, 60  
 Niacinamide (vitamin B3), 74  
 NK1 receptor, 37  
 Nonalcoholic fatty liver disease (NAFLD), 65  
 Nonsteroidal anti-inflammatory drug (NSAID), 12, 21  
 Nursing homes  
   extended care facilities, 78  
   facilities, 81  
   management, 79–80  
   nursing home care, 78–79  
   nursing staff, 80–81  
   quality of care, 79

## O

Older prescribing, dermato-pharmacology, 14–15  
 Oldest old group, 77  
 Onychomycosis, older adults, 44–47  
 Orphan receptors, 60–61

## P

Parabiosis experiments, 56  
 Pembrolizumab, 101  
 Periodic-acid Schiff (PAS) staining, 45  
 Petrolatum, 74  
 PFS. *See* Progression-free survival (PFS)  
 Phytosterols, 74  
 Platelet-derived growth factor (PDGF), 57, 58  
 Pneumocystis jirovecii pneumonia (PJP), 13  
 Polypharmacy (PP), 16, 20, 26, 34, 65, 72–73  
 Progression-free survival (PFS), 100  
 Prophylaxis, prescribing immunosuppressants, 11  
 Prurigo nodularis, 33  
 Pruritus  
   in aging skin, 73  
   case-control study, 73  
   in older adults, 72  
   and drugs, 32–33  
   elderly, 31–32, 34–36

- Pruritus (*cont.*)  
 principles of skin care, 37  
 research gaps and clinical trials, 36–37  
 senescence, eruption of, 33–34  
 and xerosis, 72, 73
- Psoriasis therapy in geriatric population  
 acitretin, 67  
 biologic medications, 67–68  
 cyclosporine, 67  
 methotrexate, 66–67  
 in older patients, 65  
 phototherapy, 66  
 physiologic changes, 65  
 topical steroids, 66  
 traditional systemics, 66  
 treatment, 68  
 the USA, 65
- R**  
 Regeneration, 56, 57  
 Rejuvenation, 59, 60  
 Retinoids, 93
- S**  
 Scabies and norwegian, 82  
 SCC. *See* Squamous cell carcinoma (SCC)  
 SCC in situ (SCCIS), 100  
 Selective estrogen receptor modulators (SERMs), 58–59  
 Seniors, 77  
 Sentinel lymph node biopsy (SLNB), 101  
 Skin aging  
 clinical presentation, 72  
 clinical studies, 58–60  
 hormones, 55–58  
 intrinsic and extrinsic, 71–72  
 and skin care, management, 73–75  
 systemic signals, 55  
 Skin barrier  
 mechanisms, skin aging, 71  
 niacinamide, 74  
 phytosterols, 74  
 Skin cancer  
 BCC (*see* Basal cell carcinoma (BCC))  
 melanoma, 101  
 in older adults, 97  
 SCC, 99–100  
 Skin care products ingredients, 74  
 Skin dermatology. *See* Dermato-pharmacology  
 Skin hydration, 72, 73, 75  
 SLNB. *See* Sentinel lymph node biopsy (SLNB)  
 Squalene/squalane, 74  
 Squamous cell carcinoma (SCC), 99–100  
 Stem cells  
 age-associated hormonal changes, 61  
 BMP signaling, 57  
 efficient growth, 61  
 tissue-specific, 56–57
- Stratum corneum  
 abnormal, 72  
 age-related changes, 72  
 anesthesia, 93  
 ceramide content, 72  
 cholesterol and ceramides, 74  
 clinical presentation, 72  
 defective acidification, 72  
 dexpanthenol, 74  
 emollients, 73  
 fatty acids, 74  
 glycerol, 74  
 lanolin, 75  
 tocopherol, 75  
 triglycerides, 74  
 xerosis management, 73
- Subungual squamous cell carcinoma, 49  
 Superficial X-ray therapy (SXRT), 100  
 Supportive skin care  
 aging skin (*see* Skin aging)care in older patients, 75  
 physiologic and morphologic cutaneous changes, 71–72  
 practitioners and specialists, 71  
 quality of life, 73  
 the United Nation's World Population Ageing Report, 71
- T**  
 Tavorole, 45  
 TCA. *See* Trichloroacetic acid (TCA)  
 Terbinafine, 46  
 Terry's nails, 41  
 TEWL. *See* Transepidermal water loss (TEWL)  
 TGF- $\beta$  signaling  
 aged mammals/mice, 57  
 BMP signaling, 57  
 CTGF, 57  
 stimulation, 57  
 Therapeutics  
 horizon, 37  
 LOE IV, 24  
 onychomycosis, 47  
 TGF- $\beta$  signaling, 57  
 Thymidine 5-monophosphate (TMP), 91  
 Tocopherol (vitamin E), 75  
 Transepidermal water loss (TEWL), 72, 74  
 Treatment, AKs patients  
 5-aminolevulinic acid and methyl aminolevulinate, 92  
 chemical peel, 93  
 CO<sub>2</sub> and Er:YAG ablative, 93  
 cryotherapy, 90, 91  
 diclofenac, 92  
 DUMP, 91  
 fluorouracil and trichloroacetic acid, 93  
 follow-up times, 90  
 5-FU, 90–91  
 imiquimod, 91

inflammation, 91  
ingenol mebutate, 91–92  
lesions, 91  
non-immunosuppressed participants, 92  
PDT, older adults, 92  
pharmacotherapy, 93  
primary care, 93  
retinoids, 93  
satisfaction and outcomes, 94  
side effects, 93  
squamous cell carcinoma, 90  
stratum corneum under anesthesia, 93  
Trichloroacetic acid (TCA), 93  
*Trichophyton rubrum*, 45  
Triglycerides, 74  
Tumors of the nail apparatus, 42  
Type 2 dominance (Th2), 33

**U**

Urea, 75  
Ustekinumab, 67

**V**

Veterans Affairs Topical Tretinoin Chemoprevention  
Trial, 93  
Vitamin B3 (niacinamide), 74

**W**

Wnt signaling, 56, 57  
Wound-healing  
  estrogen, 58  
  hormonal changes, skin aging, 56  
  skin atrophy, 56  
  TGF- $\beta$  signaling, 57

**X**

Xerosis, 33  
  and hyperpigmented patches, 34  
  management, 73  
  moisturizers, 73–75  
  prevalence, 72  
  and pruritus, 72